Effect of polyvinylpyrrolidone on the interaction of chlorin e6 with plasma proteins and its subcellular localization

10.1016/j.ejpb.2010.06.005European Journal of Pharmaceutics and Biopharmaceutics762245-252EJPB

Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model

10.1016/j.jphotobiol.2006.10.003Journal of Photochemistry and Photobiology B: Biology863207-218JPPB

The potential application of chlorin e6-polyvinylpyrrolidone formulation in photodynamic therapy

10.1039/b605772aPhotochemical and Photobiological Sciences5111031-1037PPSH

Enhanced photodynamic activity of hypericin by penetration enhancer N-methyl pyrrolidone formulations in the chick chorioallantoic membrane model

10.1016/j.canlet.2005.06.026Cancer Letters2381104-110CALE

Loss of intercellular adhesion leads to differential accumulation of hypericin in bladder cancer

10.1117/12.828461Progress in Biomedical Optics and Imaging - Proceedings of SPIE7380

Chlorin e6-polyvinylpyrrolidone as a fluorescent marker for fluorescence diagnosis of human bladder cancer implanted on the chick chorioallantoic membrane model

10.1016/j.canlet.2005.12.041Cancer Letters2451-2127-133CALE

Membrane transport enhancement of chlorin e6-polyvinylpyrrolidone and its photodynamic efficacy on the chick chorioallantoic model

10.1002/jbio.200810005Journal of Biophotonics15395-40

Fluorescence imaging and phototoxicity effects of new formulation of chlorin e6-polyvinylpyrrolidone

10.1016/j.jphotobiol.2006.02.002Journal of Photochemistry and Photobiology B: Biology842103-110JPPB

Combination of angiogenesis inhibitors increases the anti-tumor efficacy of photodynamic therapy in a human bladder tumor xenograft model

10.1117/12.828460Progress in Biomedical Optics and Imaging - Proceedings of SPIE7380

Improved formulation of photosensitizer chlorin e6 polyvinylpyrrolidone for fluorescence diagnostic imaging and photodynamic therapy of human cancer

10.1016/j.ejpb.2008.02.013European Journal of Pharmaceutics and Biopharmaceutics6931083-1093EJPB